Get the Stockscreener App
0.33
10.00%
+0.03
After Hours:
.3389
0.0089
+2.70%
Seelos Therapeutics Inc stock is currently priced at $0.33, with a 24-hour trading volume of 339.17K.
It has seen a +10.00% increased in the last 24 hours and a -41.07% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.2953 pivot point. If it approaches the $0.3372 resistance level, significant changes may occur.
Previous Close:
$0.30
Open:
$0.2975
24h Volume:
339.17K
Market Cap:
$4.51M
Revenue:
-
Net Income/Loss:
$-37.07M
P/E Ratio:
-0.4783
EPS:
-0.69
Net Cash Flow:
$-23.91M
1W Performance:
+15.55%
1M Performance:
-41.07%
6M Performance:
+84.98%
1Y Performance:
-55.14%
1D Range:
$0.2933
$0.335
52W Range:
$0.1029
$2.9924
Seelos Therapeutics Inc Stock (SEEL) Company Profile
Name
Seelos Therapeutics Inc
Sector
Industry
Phone
646 293 2100
Address
300 Park Avenue, 2nd Floor, New York
Seelos Therapeutics Inc Stock (SEEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Jul-01-21 | Initiated | Guggenheim | Buy |
| Jun-01-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-30-21 | Initiated | B. Riley Securities | Buy |
| Nov-14-19 | Initiated | The Benchmark Company | Speculative Buy |
| May-14-19 | Initiated | ROTH Capital | Buy |
View All
Seelos Therapeutics Inc Stock (SEEL) Latest News
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
Benzinga
Nasdaq Down 100 Points; US Housing Starts Surge In February
Benzinga
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Dow Jumps Over 100 Points; Hormel Foods Earnings Miss Estimates
Benzinga
Seelos Therapeutics Inc Stock (SEEL) Financials Data
Seelos Therapeutics Inc (SEEL) Net Income 2024
SEEL net income (TTM) was -$37.07 million for the quarter ending December 31, 2023, a +49.58% increase year-over-year.
Seelos Therapeutics Inc (SEEL) Cash Flow 2024
SEEL recorded a free cash flow (TTM) of -$23.91 million for the quarter ending December 31, 2023, a +61.18% increase year-over-year.
Seelos Therapeutics Inc (SEEL) Earnings per Share 2024
SEEL earnings per share (TTM) was -$13.73 for the quarter ending December 31, 2023, a +32.83% growth year-over-year.
About Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
0.56%
3.58%
Cap:
|
Volume (24h):